JHVEPhoto "Science Lessons" is a famous book by Gordon Binder, the now 89 year-old who led Amgen (NASDAQ:AMGN) as CEO from 1988-2000 and CFO from 1982-1988. It discusses Amgen's growth as a biopharmaceutical company, along with the company's core focuses on discovery and science in what is an incredibly tough industry. As we'll see throughout this article, despite Amgen's recent stock price stagnation, the company has one of the best portfolios in the industry, making it a valuable investment. Amgen Horizon ...

Amgen (AMGN) ended the recent trading session at $270, demonstrating a +1.33% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.74%. Meanwhile, the Dow experienced a drop of 0.01%, and the technology-dominated Nasdaq saw an increase of 1.68%.Shares of the world's largest biotech drugmaker have depreciated by 3.46% over the course of the past month, outperforming the Medical sector's loss of 4.72% and lagging the S&P 500's gain of 0.8%.The upcoming e ...

These drugmakers have made important moves over the past year.The biotech industry can be attractive for several reasons. Many leading biotechs develop innovative, life-saving therapies, a business that will only be phased out once we find an all-purpose cure for all illnesses. Further, biotechs often deliver better-than-average financial results during economic downturns because the products they sell are considered necessary goods.Of course, not every biotech company is worth investing in. Let's consider ...

PM Images/DigitalVision via Getty Images Introduction Over the past few years, I have increasingly focused on one major issue: the looming retirement crisis. Although every time I use the word "crisis" in a title, I feel guilty of clickbait, there's no denying that it's an appropriate use of the word, as we're increasingly moving to a situation that could see significant retirement funding shortages. The Guardian headline below is a good example of this: The Guardian My most recent article on this subje ...

Amgen (AMGN) is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health, nephrology and neuroscience markets.Thousand Oaks, CA-based Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. Biosimilar drugs are also a key part of Amgen’s growth strategy. ...

Key PointsThe iShares Biotechnology ETF (IBB) is consolidating in the upper range, suggesting a potential sector breakout.Despite modest YTD gains in the biotech sector, the recent consolidation has contracted further, hinting at energy buildup for a higher breakout.The sector ETF's key holdings are Amgen (AMGN), Vertex Pharmaceuticals (VRTX), and Gilead Sciences (GILD), which influence sector direction and momentum.5 stocks we like better than Gilead SciencesThe popular iShares Biotechnology ETF NASDAQ: IB ...

Amgen (AMGN) ended the recent trading session at $283.04, demonstrating a -0.45% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.2%. Meanwhile, the Dow experienced a drop of 0.6%, and the technology-dominated Nasdaq saw an increase of 0.11%.Shares of the world's largest biotech drugmaker witnessed a gain of 1.42% over the previous month, trailing the performance of the Medical sector with its gain of 2.21% and the S&P 500's gain of 3.32%.The in ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Amgen (AMGN) , which belongs to the Zacks Medical - Biomedical and Genetics industry.This world's largest biotech drugmaker has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 3.87%.For the last reported quarter, Amgen came out with ea ...

magnetcreative/E+ via Getty Images Eli Lilly (LLY) has been a phenomenal stock to own over the past couple of years. In early 2022, it was trading for about $230 per share, but today it trades for nearly $800. This huge run is largely due to the success of its obesity drug, "Zepbound". Eli Lilly shares now trade with a whopping price to earnings ratio of around 60. Analysts expect Eli Lilly to earn about $12.47 per share, in 2024. For 2025, the earnings estimates are at $18.16, and for 2026 the estimate ...

In this articleAMGNThe Amgen logo is displayed outside Amgen headquarters on May 17, 2023 in Thousand Oaks, California.Mario Tama | Getty ImagesAmgen is taking a new approach as it tries to stand out in a crowded field of drugmakers racing to develop the next blockbuster weight loss drug.The biotech company is testing an injectable treatment that helps people lose weight differently from the existing injections from Novo Nordisk and Eli Lilly, and other obesity medicines in development. Amgen's treatment, c ...